- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT01227668
Long-term Maintenance Study of Aripiprazole in the Treatment of Irritability Associated With Autistic Disorder
Sicherheit und Wirksamkeit von Aripiprazol bei der Langzeiterhaltungsbehandlung pädiatrischer Patienten mit Reizbarkeit im Zusammenhang mit einer autistischen Störung
The purpose of this study is to determine whether pediatric participants with irritability associated with autistic disorder who have responded to aripiprazole treatment will experience a relapse significantly later when continuing therapy with aripiprazole than will participants who receive placebo.
Studienübersicht
Status
Intervention / Behandlung
Studientyp
Einschreibung (Tatsächlich)
Phase
- Phase 4
Kontakte und Standorte
Studienorte
-
-
Alabama
-
Dothan, Alabama, Vereinigte Staaten, 36303
- Harmonex Neuroscience Research, Inc
-
-
Arizona
-
Phoenix, Arizona, Vereinigte Staaten, 85006
- Southwest Autism Research And Resource Center
-
-
California
-
Costa Mesa, California, Vereinigte Staaten, 92626
- Clinical Innovations, Inc.
-
Glendale, California, Vereinigte Staaten, 91206
- Behavioral Research Specialists, Llc
-
Palo Alto, California, Vereinigte Staaten, 94306
- Abbey Neuropsychology Clinic
-
San Francisco, California, Vereinigte Staaten, 94143
- Ucsf - Lppi
-
Stanford, California, Vereinigte Staaten, 94305
- Stanford University School Of Medicine
-
-
District of Columbia
-
Washington D.C., District of Columbia, Vereinigte Staaten, 20010
- Children'S National Medical Center
-
-
Florida
-
Gainesville, Florida, Vereinigte Staaten, 32607
- Sarkis Clinical Trials
-
Hialeah, Florida, Vereinigte Staaten, 33012
- Palm Springs Research Institute
-
Maitland, Florida, Vereinigte Staaten, 32751
- Florida Clinical Research Center, Llc
-
Miami, Florida, Vereinigte Staaten, 33155
- Miami Children'S Hospital
-
Tampa, Florida, Vereinigte Staaten, 33613
- University Of South Florida
-
-
Georgia
-
Smyrna, Georgia, Vereinigte Staaten, 30080
- Institute For Behavioral Medicine, Llc
-
-
Idaho
-
Coeur d'Alene, Idaho, Vereinigte Staaten, 83814
- Kootenai Behavioral Health Center
-
-
Kentucky
-
Louisville, Kentucky, Vereinigte Staaten, 40202
- Kosair Charities Pediatric Clinical Research Unit
-
-
Louisiana
-
Shreveport, Louisiana, Vereinigte Staaten, 71103
- Lsu Health Sciences Center
-
-
Massachusetts
-
Newton, Massachusetts, Vereinigte Staaten, 02459
- Neurocare, Inc.
-
-
Michigan
-
Bloomfield Hills, Michigan, Vereinigte Staaten, 48302
- Neurobehavioral Medicine Group
-
-
Nevada
-
Las Vegas, Nevada, Vereinigte Staaten, 89128
- Center For Psychiatry And Behavioral Medicine, Inc
-
-
New Jersey
-
Gibbsboro, New Jersey, Vereinigte Staaten, 08026
- Clinical Research Center Of New Jersey
-
Toms River, New Jersey, Vereinigte Staaten, 08755
- Children'S Specialized Hosp
-
-
New York
-
Stony Brook, New York, Vereinigte Staaten, 11794
- Stony Brook University School Of Medicine
-
-
North Carolina
-
Chapel Hill, North Carolina, Vereinigte Staaten, 27517
- Unc Chapel Hill
-
-
Ohio
-
Cleveland, Ohio, Vereinigte Staaten, 44106
- University Hospitals Case Medical Center
-
Cleveland, Ohio, Vereinigte Staaten, 44104
- Cleveland Clinic
-
Columbus, Ohio, Vereinigte Staaten, 43210
- The Ohio State University Nisonger Center
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Vereinigte Staaten, 73116
- Cutting Edge Research Group
-
Oklahoma City, Oklahoma, Vereinigte Staaten, 73117
- Ou Physician'S Child Study Center
-
Tulsa, Oklahoma, Vereinigte Staaten, 74104
- Tulsa Clinical Research, Llc
-
-
Oregon
-
Gresham, Oregon, Vereinigte Staaten, 97030
- Cyn3rgy Research
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Vereinigte Staaten, 19124
- Drexel University College Of Medicine
-
Pittsburgh, Pennsylvania, Vereinigte Staaten, 15203
- Western Psychiatric Institute And Clinic
-
-
Tennessee
-
Kingsport, Tennessee, Vereinigte Staaten, 37660
- Holston Medical Group
-
-
Texas
-
DeSoto, Texas, Vereinigte Staaten, 75115
- Insite Clinical Research
-
-
Utah
-
Clinton, Utah, Vereinigte Staaten, 84015
- Ericksen Research And Development
-
-
Virginia
-
Norfolk, Virginia, Vereinigte Staaten, 23510
- Childrens Specialty Gr., Pllc
-
Richmond, Virginia, Vereinigte Staaten, 23298
- Virginia Treatment Center For Children
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Key Inclusion Criteria:
- Male or female children or adolescents, 6 to 17 years of age, inclusive, at the time of the baseline visit
- Meets current diagnostic criteria of the Diagnostic and Statistical Manual-of Mental Disorders IV-Text Revised for autistic disorder and displays behaviors such as tantrums, aggression, self-injurious behavior, or a combination of these problems. Diagnosis of autistic disorder will be confirmed by the Autism Diagnostic Interview-Revised.
- Participant or designated guardian or caregiver is able to comprehend and satisfactorily comply with the protocol requirements, in the opinion of the investigator.
- Demonstrates behaviors such as tantrums, aggression, or self-injury or a combination of these problems
- An Aberrant Behavior Checklist Irritability subscale score ≥18 AND a Clinical Global Impressions Severity score ≥4 at the Screening and Baseline Visits.
- Mental age of at least 24 months
Key Exclusion Criteria:
- Treatment resistant to neuroleptic medication, based on lack of therapeutic response to 2 different neuroleptics after treatment for at least 3 weeks each.
- Previous treatment with aripiprazole for at least 3 weeks duration at an adequate daily dose, without demonstrating a clinically meaningful response.
- Lifetime diagnosis of bipolar disorder, psychosis, or schizophrenia, or a current diagnosis of major depressive disorder
- Diagnosis of Pervasive Developmental Disorder-Not Otherwise Specified, Asperger's Syndrome, Rett's Syndrome, childhood disintegrative disorder, or Fragile X Syndrome
- History of neuroleptic malignant syndrome
- At significant risk for suicide based on history or routine psychiatric status examination
- A seizure within the past year
- History of severe head trauma or stroke
- History or current evidence of any unstable medical conditions that would expose the patient to undue risk of a significant adverse event or interfere with assessments of safety or efficacy during the course of the trial
- Weight lower than 15 kg
- Known allergy or hypersensitivity to aripiprazole or other dihidrocarbostyrils
- History of a clinically significant low white blood cell count or a drug-induced leukopenia/neutropenia
- Any other medically significant abnormal laboratory test or vital sign result or electrocardiogram finding
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Vervierfachen
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Placebo-Komparator: Placebo
|
Tablets, oral, 0 mg, once daily, 16 weeks |
|
Experimental: Aripiprazol
|
Tablets, oral, 2-15 mg, once daily, 13-42 weeks
Andere Namen:
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Percentage of Patients Relapsing by Week 16
Zeitfenster: From end of Phase 1 (Date of randomization) to Week 16 of Phase 2 and end of treatment
|
Time of relapse=date when patient meets relapse criteria. There are 4 definitions for relapse: 1. Patient meets the following criteria for 2 consecutive visits: (a) Aberrant Behavior Checklist Irritability score ≥25% than score at end of Phase 1 AND (b) Clinical Global Impression Improvement scale rating of 'Much Worse' or 'Very Much Worse' relative to rating at end of Phase 1. If relapse criteria met at 1 visit, 2nd visit should occur in about 1 week to reevaluate whether relapse criteria are still met. 2. Patient discontinues for "Lost to Follow-up" after a visit in which he or she met Definition 1 criteria (a&b). 3. Patient begins a prohibited drug (whether a study investigator or outside source prescribed) to treat worsening symptoms of irritability of autistic disorder after a visit where patient met Definition 1 criteria (a&b). 4. Patient discontinues due to hospitalization for worsening symptoms of irritability or due to lack of efficacy based on investigator's assessment. |
From end of Phase 1 (Date of randomization) to Week 16 of Phase 2 and end of treatment
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Adjusted Mean Change From Baseline to Week 16 on the Aberrant Behavior Checklist Irritability (ABC-I) Subscale Score (Last Observation Carried Forward [LOCF])
Zeitfenster: From Baseline (end of Phase 1) to Week 16 of Phase 2
|
ABC is an informant-based checklist used to assess and classify problem behaviors of children and adolescents with mental retardation. The 58 items are rated on a 4-point scale (0=not at all a problem to 3=the problem is severe in degree), and resolve into 5 subscales: 1) irritability, agitation; 2) lethargy, social withdrawal; 3) stereotypic behavior; 4) hyperactivity, noncompliance; and 5) inappropriate speech. The ABC can be completed by parents, special educators, psychologists, direct caregivers, nurses, and others knowing the participant. Psychometric assessment of the ABC indicates that its subscales have high internal consistency, adequate reliability, and established validity. The ABC-I Subscale Score ranges from 0 to 45, with a negative change in score signifying improvement. LOCF data set includes data recorded at a given visit or, if no observation was recorded at that visit, data carried forward from the prior visit. chg=change; BL=baseline; APR=aripiprazole; vs=versus. |
From Baseline (end of Phase 1) to Week 16 of Phase 2
|
|
Change From Baseline in Mean Clinical Global Impression Improvement (CGI-I) Scale Score at Week 16 (Last Observation Carried Forward [LOCF])
Zeitfenster: From Baseline (end of Phase 1) to Week 16 of Phase 2
|
CG-I rating scale permits global evaluation of patient's improvement over time. At baseline (BL), CGI Severity of Illness assessment is performed, in which the clinician rates severity of patient's condition on a 7-point scale ranging from 1=no symptoms to 7=very severe symptoms. Higher total score=worse symptoms. At subsequent visits, clinician assesses patient's improvement relative to symptoms at baseline on CGI-I 7-point scale ranging from 1=very much improved to 7=very much worse. Since the drug targets irritability symptoms, the CGI focuses on severity of irritability secondary to autistic disorder. Lower score=more improved symptoms. LOCF data set includes data recorded at a given visit or, if nothing recorded, data areccarried forward from the prior visit. For secondary endpoints (endpt), hierarchical testing was used to keep overall experiment-wise type I error rate to <=0.05. diff=difference; IS=irritability scale; PA=primary analysis; signif=significance/significantly. |
From Baseline (end of Phase 1) to Week 16 of Phase 2
|
|
Number of Participants With Death as Outcome, Serious Adverse Events (SAEs), and Adverse Events (AEs) Leading to Discontinuation During Phase 1
Zeitfenster: Up to 26 weeks
|
AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. |
Up to 26 weeks
|
Andere Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Number of Participants With Death as Outcome, Serious Adverse Events (SAEs), Adverse Events (AEs) Leading to Discontinuation, and Treatment-related AEs During Phase 2
Zeitfenster: Weekly from Weeks 1 through 16 (end of treatment) of Phase 2
|
AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Treatment-related=having certain, probable, possible, or missing relationship to study drug. |
Weekly from Weeks 1 through 16 (end of treatment) of Phase 2
|
Mitarbeiter und Ermittler
Publikationen und hilfreiche Links
Allgemeine Veröffentlichungen
- Findling RL, Mankoski R, Timko K, Lears K, McCartney T, McQuade RD, Eudicone JM, Amatniek J, Marcus RN, Sheehan JJ. A randomized controlled trial investigating the safety and efficacy of aripiprazole in the long-term maintenance treatment of pediatric patients with irritability associated with autistic disorder. J Clin Psychiatry. 2014 Jan;75(1):22-30. doi: 10.4088/jcp.13m08500.
- Iffland M, Livingstone N, Jorgensen M, Hazell P, Gillies D. Pharmacological intervention for irritability, aggression, and self-injury in autism spectrum disorder (ASD). Cochrane Database Syst Rev. 2023 Oct 9;10(10):CD011769. doi: 10.1002/14651858.CD011769.pub2.
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Geschätzt)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- CN138-603
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .